Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses in Patients With Chronically Rejecting Renal Allografts.

Shiu KY, Stringer D, McLaughlin L, Shaw O, Brookes P, Burton H, Wilkinson H, Douthwaite H, Tsui TL, Mclean A, Hilton R, Griffin S, Geddes C, Ball S, Baker R, Roufosse C, Horsfield C, Dorling A.

Front Immunol. 2020 Feb 5;11:79. doi: 10.3389/fimmu.2020.00079. eCollection 2020.

2.

Autologous Stem Cell Transplant for the Treatment of Type I Crystal Cryoglobulinemic Glomerulonephritis Caused by Monoclonal Gammopathy of Renal Significance (MGRS).

Kousios A, Duncan N, Charif R, Tam FWK, Levy J, Cook HT, Pusey CD, Roufosse C, Chaidos A.

Kidney Int Rep. 2019 May 22;4(9):1342-1348. doi: 10.1016/j.ekir.2019.05.014. eCollection 2019 Sep. No abstract available.

3.

Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial.

Nikolopoulou A, Condon M, Turner-Stokes T, Cook HT, Duncan N, Galliford JW, Levy JB, Lightstone L, Pusey CD, Roufosse C, Cairns TD, Griffith ME.

BMC Nephrol. 2019 Sep 6;20(1):352. doi: 10.1186/s12882-019-1539-z.

4.

Predicting long-term renal and patient survival by clinicopathological features in elderly patients undergoing a renal biopsy in a UK cohort.

Navaratnarajah A, Sambasivan K, Cook TH, Pusey C, Roufosse C, Willicombe M.

Clin Kidney J. 2019 Feb 28;12(4):512-520. doi: 10.1093/ckj/sfz006. eCollection 2019 Aug.

5.

IgG4-related disease in a multi-ethnic community: clinical characteristics and association with malignancy.

Poo SX, Tham CSW, Smith C, Lee J, Cairns T, Galliford J, Hamdulay S, Jacyna M, Levy JB, McAdoo SP, Roufosse C, Wernig F, Mason JC, Pusey CD, Tam FWK, Tomlinson JAP.

QJM. 2019 Oct 1;112(10):763-769. doi: 10.1093/qjmed/hcz149.

PMID:
31225617
6.

Plasmacytoma-Like Posttransplant Lymphoproliferative Disease in a Disused Arteriovenous Fistula: The Importance of Histopathology.

Kousios A, Storey R, Troy-Barnes E, Hamady M, Salisbury E, Duncan N, Charif R, Tam FWK, Cook HT, Crane J, Chaidos A, Roufosse C, Flora R.

Kidney Int Rep. 2019 Feb 13;4(5):749-755. doi: 10.1016/j.ekir.2019.02.003. eCollection 2019 May. No abstract available.

7.

Clinical-pathological correlations in post-transplant thrombotic microangiopathy.

Broecker V, Bardsley V, Torpey N, Perera R, Montero R, Dorling A, Bentall A, Neil D, Willicombe M, Berry M, Roufosse C.

Histopathology. 2019 Jul;75(1):88-103. doi: 10.1111/his.13855.

PMID:
30851188
8.

Proliferative glomerulonephritis with monoclonal Ig deposits (PGNMID): diagnostic and treatment challenges for the nephrologist!

Kousios A, Duncan N, Tam FWK, Chaidos A, Cook HT, Roufosse C, Charif R.

Kidney Int. 2019 Feb;95(2):467-468. doi: 10.1016/j.kint.2018.10.016. No abstract available.

9.

Successful management of post-transplant focal segmental glomerulosclerosis with therapeutic plasma exchange and rituximab.

Koutroutsos K, Charif R, Moran L, Moss J, Cook T, Roufosse C, Pusey C, Taube D, Loucaidou M.

Clin Exp Nephrol. 2019 May;23(5):700-709. doi: 10.1007/s10157-019-01690-0. Epub 2019 Jan 14.

PMID:
30637591
10.

Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection.

Dominy KM, Willicombe M, Al Johani T, Beckwith H, Goodall D, Brookes P, Cook HT, Cairns T, McLean A, Roufosse C.

Kidney Int Rep. 2018 Sep 18;4(1):148-158. doi: 10.1016/j.ekir.2018.09.005. eCollection 2019 Jan.

11.

Shared alloimmune responses against blood and transplant donors result in adverse clinical outcomes following blood transfusion post-renal transplantation.

Hassan S, Regan F, Brown C, Harmer A, Anderson N, Beckwith H, Roufosse CA, Santos-Nunez E, Brookes P, Taube D, Willicombe M.

Am J Transplant. 2019 Jun;19(6):1720-1729. doi: 10.1111/ajt.15233. Epub 2019 Jan 28.

12.

Smoldering Myeloma Presenting with Renal Histopathology of Monoclonal Gammopathy of Renal Significance: Adding to the Complexity.

Kousios A, Duncan N, Charif R, Roufosse C.

J Am Soc Nephrol. 2018 Dec;29(12):2901. doi: 10.1681/ASN.2018080864. Epub 2018 Oct 30. No abstract available.

13.

The expanding spectrum of antibody-mediated rejection: Should we include cases where no anti-HLA donor-specific antibody is detected?

Randhawa P, Roufosse C.

Am J Transplant. 2019 Mar;19(3):622-624. doi: 10.1111/ajt.15114. Epub 2018 Oct 1. No abstract available.

14.

A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology.

Roufosse C, Simmonds N, Clahsen-van Groningen M, Haas M, Henriksen KJ, Horsfield C, Loupy A, Mengel M, Perkowska-Ptasińska A, Rabant M, Racusen LC, Solez K, Becker JU.

Transplantation. 2018 Nov;102(11):1795-1814. doi: 10.1097/TP.0000000000002366. Review. Erratum in: Transplantation. 2018 Dec;102(12):e497.

15.

The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.

Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, Nankivell BJ, Halloran PF, Colvin RB, Akalin E, Alachkar N, Bagnasco S, Bouatou Y, Becker JU, Cornell LD, van Huyen JPD, Gibson IW, Kraus ES, Mannon RB, Naesens M, Nickeleit V, Nickerson P, Segev DL, Singh HK, Stegall M, Randhawa P, Racusen L, Solez K, Mengel M.

Am J Transplant. 2018 Feb;18(2):293-307. doi: 10.1111/ajt.14625. Epub 2018 Jan 21.

16.

Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment.

Beckwith H, Medjeral-Thomas N, Galliford J, Griffith M, Levy J, Lightstone L, Palmer A, Roufosse C, Pusey C, Cook HT, Cairns T.

Nephrol Dial Transplant. 2017 Jan 1;32(suppl_1):i123-i128. doi: 10.1093/ndt/gfw326.

17.

The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology.

Loupy A, Haas M, Solez K, Racusen L, Glotz D, Seron D, Nankivell BJ, Colvin RB, Afrouzian M, Akalin E, Alachkar N, Bagnasco S, Becker JU, Cornell L, Drachenberg C, Dragun D, de Kort H, Gibson IW, Kraus ES, Lefaucheur C, Legendre C, Liapis H, Muthukumar T, Nickeleit V, Orandi B, Park W, Rabant M, Randhawa P, Reed EF, Roufosse C, Seshan SV, Sis B, Singh HK, Schinstock C, Tambur A, Zeevi A, Mengel M.

Am J Transplant. 2017 Jan;17(1):28-41. doi: 10.1111/ajt.14107.

18.

The natural history of immunoglobulin M nephropathy in adults.

Connor TM, Aiello V, Griffith M, Cairns T, Roufosse CA, Cook HT, Pusey CD.

Nephrol Dial Transplant. 2017 May 1;32(5):823-829. doi: 10.1093/ndt/gfw063.

19.

Banff Borderline Changes Suspicious for Acute T Cell-Mediated Rejection: Where Do We Stand?

Becker JU, Chang A, Nickeleit V, Randhawa P, Roufosse C.

Am J Transplant. 2016 Sep;16(9):2654-60. doi: 10.1111/ajt.13784. Epub 2016 May 5.

20.

Immune Complex-Type Deposits in the Fischer-344 to Lewis Rat Model of Renal Transplantation and a Subset of Human Transplant Glomerulopathy.

Grau V, Zeuschner P, Immenschuh S, Bockmeyer CL, Zell S, Wittig J, Säuberlich K, Abbas M, Padberg W, Meyer-Schwesinger C, von Brandenstein M, Schlosser M, Dieplinger G, Galliford J, Clarke C, Roufosse C, Becker JU.

Transplantation. 2016 May;100(5):1004-14. doi: 10.1097/TP.0000000000001068.

PMID:
26895216
21.

Multiplexed color-coded probe-based gene expression assessment for clinical molecular diagnostics in formalin-fixed paraffin-embedded human renal allograft tissue.

Adam B, Afzali B, Dominy KM, Chapman E, Gill R, Hidalgo LG, Roufosse C, Sis B, Mengel M.

Clin Transplant. 2016 Mar;30(3):295-305. doi: 10.1111/ctr.12689. Epub 2016 Feb 3.

PMID:
26729350
22.

Tubuloreticular Inclusions in Renal Allografts Associate with Viral Infections and Donor-Specific Antibodies.

Willicombe M, Moss J, Moran L, Brookes P, Santos-Nunez E, McLean AG, Cairns T, Taube D, Cook TH, Roufosse C.

J Am Soc Nephrol. 2016 Jul;27(7):2188-95. doi: 10.1681/ASN.2015050478. Epub 2015 Nov 27.

23.

Peritubular Capillary Basement Membrane Multilayering in Renal Allograft Biopsies of Patients With De Novo Donor-Specific Antibodies.

de Kort H, Willicombe M, Brookes P, Moran LB, Santos-Nunez E, Galliford JW, Taube D, McLean AG, Moss J, Cook HT, Roufosse C.

Transplantation. 2016 Apr;100(4):889-97. doi: 10.1097/TP.0000000000000908.

PMID:
26413993
24.

The role of electron microscopy in renal allograft biopsy evaluation.

de Kort H, Moran L, Roufosse C.

Curr Opin Organ Transplant. 2015 Jun;20(3):333-42. doi: 10.1097/MOT.0000000000000183. Review.

PMID:
25944229
25.

Pulmonary Inflammation Impacts on CYP1A1-Mediated Respiratory Tract DNA Damage Induced by the Carcinogenic Air Pollutant Benzo[a]pyrene.

Arlt VM, Krais AM, Godschalk RW, Riffo-Vasquez Y, Mrizova I, Roufosse CA, Corbin C, Shi Q, Frei E, Stiborova M, van Schooten FJ, Phillips DH, Spina D.

Toxicol Sci. 2015 Aug;146(2):213-25. doi: 10.1093/toxsci/kfv086. Epub 2015 Apr 23.

26.

B-lymphocytes support and regulate indirect T-cell alloreactivity in individual patients with chronic antibody-mediated rejection.

Shiu KY, McLaughlin L, Rebollo-Mesa I, Zhao J, Semik V, Cook HT, Roufosse C, Brookes P, Bowers RW, Galliford J, Taube D, Lechler RI, Hernandez-Fuentes MP, Dorling A.

Kidney Int. 2015 Sep;88(3):560-8. doi: 10.1038/ki.2015.100. Epub 2015 Apr 1.

27.

Use of Quantitative Real Time Polymerase Chain Reaction to Assess Gene Transcripts Associated With Antibody-Mediated Rejection of Kidney Transplants.

Dominy KM, Roufosse C, de Kort H, Willicombe M, Brookes P, Behmoaras JV, Petretto EG, Galliford J, Choi P, Taube D, Cook HT, Mclean AG.

Transplantation. 2015 Sep;99(9):1981-8. doi: 10.1097/TP.0000000000000621.

28.

Value of antibodies to free light chains in immunoperoxidase studies of renal biopsies.

Owen-Casey MP, Sim R, Cook HT, Roufosse CA, Gillmore JD, Gilbertson JA, Hutchison CA, Howie AJ.

J Clin Pathol. 2014 Aug;67(8):661-6. doi: 10.1136/jclinpath-2014-202231. Epub 2014 May 9.

29.

Diagnosis of early pancreas graft failure via antibody-mediated rejection: single-center experience with 256 pancreas transplantations.

de Kort H, Mallat MJ, van Kooten C, de Heer E, Brand-Schaaf SH, van der Wal AM, Roufosse C, Roelen DL, Bruijn JA, Claas FH, de Fijter JW, Bajema IM.

Am J Transplant. 2014 Apr;14(4):936-42. doi: 10.1111/ajt.12624. Epub 2014 Feb 12.

30.

Occult microscopic polyangiitis presenting as pyrexia of unknown origin.

Ziaj S, Mitchell C, Roufosse C, Dubrey SW.

Br J Hosp Med (Lond). 2014 Mar;75(3):172-3. No abstract available.

PMID:
24621636
31.

Acute cellular rejection: impact of donor-specific antibodies and C4d.

Willicombe M, Roufosse C, Brookes P, McLean AG, Galliford J, Cairns T, Cook TH, Taube D.

Transplantation. 2014 Feb 27;97(4):433-9. doi: 10.1097/01.TP.0000437431.97108.8f.

PMID:
24430742
32.

Pancreas transplantation, antibodies and rejection: where do we stand?

de Kort H, Roufosse C, Bajema IM, Drachenberg CB.

Curr Opin Organ Transplant. 2013 Jun;18(3):337-44. doi: 10.1097/MOT.0b013e3283614a5c. Review.

PMID:
23619511
33.

Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.

Lawrence C, Willicombe M, Brookes PA, Santos-Nunez E, Bajaj R, Cook T, Roufosse C, Taube D, Warrens AN.

Transplantation. 2013 Jan 27;95(2):341-6. doi: 10.1097/TP.0b013e3182743cfa.

PMID:
23197178
34.

Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies.

de Kort H, Willicombe M, Brookes P, Dominy KM, Santos-Nunez E, Galliford JW, Chan K, Taube D, McLean AG, Cook HT, Roufosse C.

Am J Transplant. 2013 Feb;13(2):485-92. doi: 10.1111/j.1600-6143.2012.04325.x. Epub 2012 Nov 21.

35.

Peritubular capillary basement membrane multilayering on electron microscopy: a useful marker of early chronic antibody-mediated damage.

Roufosse CA, Shore I, Moss J, Moran LB, Willicombe M, Galliford J, Chan KK, Brookes PA, de Kort H, McLean AG, Taube D, Cook HT.

Transplantation. 2012 Aug 15;94(3):269-74.

PMID:
22790448
36.

De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy.

Willicombe M, Brookes P, Sergeant R, Santos-Nunez E, Steggar C, Galliford J, McLean A, Cook TH, Cairns T, Roufosse C, Taube D.

Transplantation. 2012 Jul 27;94(2):172-7. doi: 10.1097/TP.0b013e3182543950.

PMID:
22735711
37.

ACB-PCR measurement of H-ras codon 61 CAA→CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues.

Wang Y, Arlt VM, Roufosse CA, McKim KL, Myers MB, Phillips DH, Parsons BL.

Environ Mol Mutagen. 2012 Aug;53(7):495-504. doi: 10.1002/em.21710. Epub 2012 Jun 25.

PMID:
22729866
38.

A case of chronic antibody-mediated rejection in the making.

Bravou V, Galliford J, McLean A, Willicombe M, Taube D, Cook HT, Roufosse C.

Clin Nephrol. 2013 Oct;80(4):306-9. doi: 10.5414/CN107462.

PMID:
22579273
39.

Dissociation of ferritin and hepcidin in a case of adult-onset Still's disease.

Tharmalingam H, Ashby DR, Busbridge M, Roufosse C, Cairns TD.

Int J Hematol. 2011 Oct;94(4):408-409. doi: 10.1007/s12185-011-0926-4. Epub 2011 Sep 23. No abstract available.

PMID:
21948263
40.

Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial.

Chan K, Taube D, Roufosse C, Cook T, Brookes P, Goodall D, Galliford J, Cairns T, Dorling A, Duncan N, Hakim N, Palmer A, Papalois V, Warrens AN, Willicombe M, McLean AG.

Transplantation. 2011 Oct 15;92(7):774-80. doi: 10.1097/TP.0b013e31822ca7ca.

PMID:
21836540
41.

Paraprotein 'zippers'.

Bravou V, McLean AG, Loucaidou M, Cairns TD, Cook HT, Roufosse CA.

Kidney Int. 2011 Jul;80(1):126. doi: 10.1038/ki.2011.54. No abstract available.

42.

Antibody-mediated rejection after alemtuzumab induction: incidence, risk factors, and predictors of poor outcome.

Willicombe M, Roufosse C, Brookes P, Galliford JW, McLean AG, Dorling A, Warrens AN, Cook TH, Cairns TD, Taube D.

Transplantation. 2011 Jul 27;92(2):176-82. doi: 10.1097/TP.0b013e318222c9c6.

PMID:
21637139
43.

Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy.

Willicombe M, Brookes P, Santos-Nunez E, Galliford J, Ballow A, Mclean A, Roufosse C, Cook HT, Dorling A, Warrens AN, Cairns T, Taube D.

Am J Transplant. 2011 Mar;11(3):470-7. doi: 10.1111/j.1600-6143.2010.03421.x. Epub 2011 Feb 7.

44.

Acute renal failure due to immune reconstitution inflammatory interstitial nephritis in an HIV-positive patient.

Croucher A, Vera J, Akolo C, Roufosse C, Holden B, Cooke G.

AIDS. 2010 Jul 17;24(11):1788-90. doi: 10.1097/QAD.0b013e328339d083. No abstract available.

PMID:
20588107
45.

Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice.

Arlt VM, Zuo J, Trenz K, Roufosse CA, Lord GM, Nortier JL, Schmeiser HH, Hollstein M, Phillips DH.

Int J Cancer. 2011 Jan 1;128(1):21-32. doi: 10.1002/ijc.25324.

46.

Lupus podocytopathy.

Shea-Simonds P, Cairns TD, Roufosse C, Cook T, Vyse TJ.

Rheumatology (Oxford). 2009 Dec;48(12):1616-8. doi: 10.1093/rheumatology/kep256. Epub 2009 Aug 27. No abstract available.

PMID:
19713441
47.

Pathological predictors of prognosis in immunoglobulin A nephropathy: a review.

Roufosse CA, Cook HT.

Curr Opin Nephrol Hypertens. 2009 May;18(3):212-9. doi: 10.1097/MNH.0b013e328329605c. Review.

PMID:
19300248
48.

Stem cells and renal regeneration.

Roufosse C, Cook HT.

Nephron Exp Nephrol. 2008;109(2):e39-45. doi: 10.1159/000139989. Epub 2008 Jun 18. Review.

49.

Genes expressed by both mesangial cells and bone marrow-derived cells underlie genetic susceptibility to crescentic glomerulonephritis in the rat.

Smith J, Lai PC, Behmoaras J, Roufosse C, Bhangal G, McDaid JP, Aitman T, Tam FW, Pusey CD, Cook HT.

J Am Soc Nephrol. 2007 Jun;18(6):1816-23. Epub 2007 May 2.

50.

Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome.

Prodromidi EI, Poulsom R, Jeffery R, Roufosse CA, Pollard PJ, Pusey CD, Cook HT.

Stem Cells. 2006 Nov;24(11):2448-55. Epub 2006 Jul 27.

Supplemental Content

Loading ...
Support Center